Immunological considerations for developing antibody therapeutics for Influenza A

Area of Science:

• Virology and Immunology
• Infectious Diseases
• Therapeutic Antibody Development

Background:

• Influenza infections can lead to severe illness, complications, and hospitalization.
• Current influenza treatments offer limited efficacy for hospitalized patients.
• Human monoclonal antibodies (mAbs) are emerging as potential therapeutic options for severe influenza.

Purpose of the Study:

• To discuss the potential for antibody-dependent enhancement (ADE) of influenza illness by therapeutic monoclonal antibodies (mAbs).
• To review known ADE mechanisms and their relevance to anti-influenza HA-stalk and M2 antibodies.
• To address concerns regarding ADE in the context of developing mAb-based influenza therapies.

Main Methods:

• Review of existing literature on antibody-dependent enhancement (ADE) mechanisms.
• Analysis of preliminary clinical viral challenge study results for anti-HA-stalk and anti-M2 mAbs.
• Discussion of immunologic effects beyond direct viral neutralization by mAbs.

Main Results:

• Antibody-dependent enhancement (ADE) is well-described for Dengue virus but not extensively for influenza.
• Preliminary data suggest potential for enhanced viral shedding with anti-HA-stalk mAbs.
• No enhanced viral shedding was observed in clinical trials with the anti-M2 mAb TCN-032.

Conclusions:

• While mAbs offer therapeutic potential for influenza, the risk of ADE must be carefully considered.
• Different antibody targets (e.g., HA-stalk vs. M2) may have varying ADE profiles.
• Further research is needed to fully understand and mitigate ADE risks associated with influenza mAbs.